Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

467 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-19

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop a lung cancer diagnosis tool using a multi-omics approach based on liquid biopsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

NCT04156360

Healthy Pulmonary Nodule

UNKNOWN

Biomarkers for Diagnosis of Lung Cancer

NCT02050100

Lung Cancer Lung Neoplasm

COMPLETED

A Preliminary Study on the Detection of Plasma Markers in Early Diagnosis for Lung Cancer

NCT04558255

Lung Cancer

UNKNOWN

A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.

NCT06733311

Early-Stage Lung Cancer NSCLC Pulmonary Nodule

RECRUITING

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer

NCT07057102

Non Small Cell Lung Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening process to determine eligibility of study entry. Peripheral blood, tissue sample and imaging examinations of eligible patients will be collected for further analysis. Data collected will be used to develop a multi-omics lung cancer diagnosis model.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Male or female, age equal to or greater than 40 years old and less than 75 years old
* Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers
* Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling
* The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc.

Exclusion Criteria

* Unable to obtain sufficient and qualified blood samples
* Female subjects who are pregnant or breastfeeding
* Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation
* Patients who have received blood transfusion within 7 days before blood sampling
* Patients who have received anti-infection treatment within 14 days before blood collection
* Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc.
* Patients who suffered from other malignant tumors or multiple primary tumors at the same time
* Pathological confirmed benign lesions by tissue biopsy or surgery
* Insufficient sample for a confirmed pathological diagnosis
* Lung cancer patients with ground glass nodules on CT imaging.

Minimum Eligible Age

40 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No